Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Alberge JB"'
Autor:
Tahri S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Harvard Medical School, Boston, MA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA.; Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands., Piccinelli S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Harvard Medical School, Boston, MA., Su NK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Harvard Medical School, Boston, MA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA., Lampe L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Harvard Medical School, Boston, MA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA.; Medical Department, Christian-Albrechts University, Kiel, Germany., Dong H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Vergara Cadavid J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Boiarsky R; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA.; Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, MA., Papazian N; Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands., Lightbody ED; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Harvard Medical School, Boston, MA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA., Cao A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Harvard Medical School, Boston, MA., Alberge JB; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Harvard Medical School, Boston, MA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA., Ferrari de Andrade L; Precision Immunology Institute, Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai Hospital, New York, NY., Rahmat M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Harvard Medical School, Boston, MA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA., Shen Y; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Cancer Science Institute of Singapore, National University of Singapore Cancer Science, Singapore, Singapore.; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Blanco Fernández L; Clínica Universidad de Navarra, Center for Applied Medical Research, CIBERONC, IDISNA, Pamplona, Spain., Zabaleta A; Clínica Universidad de Navarra, Center for Applied Medical Research, CIBERONC, IDISNA, Pamplona, Spain., Günther A; Medical Department, Christian-Albrechts University, Kiel, Germany., Getz G; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA.; Krantz Family Center for Cancer Research and Deptartment of Pathology, Massachusetts General Hospital, Boston, MA.; Department of Pathology, Harvard Medical School, Boston, MA., Sonneveld P; Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands., Cupedo T; Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands., Wucherpfennig KW; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Ghobrial IM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Harvard Medical School, Boston, MA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA., Romee R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Harvard Medical School, Boston, MA.
Publikováno v:
Blood advances [Blood Adv] 2024 Oct 22; Vol. 8 (20), pp. 5365-5370.
Autor:
Cordas Dos Santos DM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Toenges R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Bertamini L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Hematology, Erasmus MC Cancer Institute Rotterdam, Rotterdam, The Netherlands., Alberge JB; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Ghobrial IM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. irene_ghobrial@dfci.harvard.edu.; Harvard Medical School, Boston, MA, USA. irene_ghobrial@dfci.harvard.edu.; Broad Institute of Harvard and MIT, Cambridge, MA, USA. irene_ghobrial@dfci.harvard.edu.
Publikováno v:
Nature reviews. Cancer [Nat Rev Cancer] 2024 Oct 16. Date of Electronic Publication: 2024 Oct 16.
Autor:
Rahmat M; Dana-Farber Cancer Institute, Boston, MA, United States., Clement K; University of Utah, Salt Lake City, UT, United States., Alberge JB; Dana-Farber Cancer Institute, Boston, MA, United States., Sklavenitis-Pistofidis R; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States., Kodgule R; University of Michigan-Ann Arbor, Ann Arbor, MI, United States., Fulco CP; Broad Institute of MIT and Harvard, United States., Heilpern-Mallory D; Dana-Farber Cancer Institute, Harvard Medical School, United States., Nilsson K; Northeastern University, United States., Dorfman D; Brigham and Women's Hospital, Boston, MA, United States., Engreitz JM; Stanford University, United States., Getz G; Broad Institute, Cambridge, MA, United States., Pinello L; Massachusetts General Hospital, Boston, United States., Ryan R; University of Michigan-Ann Arbor, Ann Arbor, MI, United States., Ghobrial IM; Dana-Farber Cancer Institute, Boston, MA, United States.
Publikováno v:
Cancer research [Cancer Res] 2024 Sep 23. Date of Electronic Publication: 2024 Sep 23.
Autor:
Cordas Dos Santos DM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.; Department of Medicine III-Hematology/Oncology, LMU University Hospital, LMU Munich, Munich, Germany., Tix T; Department of Medicine III-Hematology/Oncology, LMU University Hospital, LMU Munich, Munich, Germany., Shouval R; Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Weill Cornell Medical College, New York, NY, USA., Gafter-Gvili A; Department of Medicine A and Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, Petah-Tikva, Israel.; Tel Aviv University, Tel Aviv, Israel., Alberge JB; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA., Cliff ERS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Program on Regulation, Therapeutics and Law, Brigham and Women's Hospital, Boston, MA, USA., Theurich S; Department of Medicine III-Hematology/Oncology, LMU University Hospital, LMU Munich, Munich, Germany.; German Cancer Consortium, Partner Site Munich, Munich, Germany., von Bergwelt-Baildon M; Department of Medicine III-Hematology/Oncology, LMU University Hospital, LMU Munich, Munich, Germany.; German Cancer Consortium, Partner Site Munich, Munich, Germany., Ghobrial IM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA., Subklewe M; Department of Medicine III-Hematology/Oncology, LMU University Hospital, LMU Munich, Munich, Germany.; German Cancer Consortium, Partner Site Munich, Munich, Germany., Perales MA; Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Weill Cornell Medical College, New York, NY, USA., Rejeski K; Department of Medicine III-Hematology/Oncology, LMU University Hospital, LMU Munich, Munich, Germany. rejeskik@mskcc.org.; Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. rejeskik@mskcc.org.; Department of Medicine, Weill Cornell Medical College, New York, NY, USA. rejeskik@mskcc.org.; German Cancer Consortium, Partner Site Munich, Munich, Germany. rejeskik@mskcc.org.
Publikováno v:
Nature medicine [Nat Med] 2024 Sep; Vol. 30 (9), pp. 2667-2678. Date of Electronic Publication: 2024 Jul 08.
Autor:
Nadeem O; Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Aranha MP; Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute, Boston, MA, USA., Redd R; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Timonian M; Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute, Boston, MA, USA., Magidson S; Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Lightbody ED; Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute, Boston, MA, USA., Alberge JB; Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute, Boston, MA, USA., Bertamini L; Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Dutta AK; Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., El-Khoury H; Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Bustoros M; Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Division of Hematology and Medical Oncology, Meyer Cancer Center, New York-Presbyterian Hospital, New York, New York, USA., Laubach JP; Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Bianchi G; Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., O'Donnell E; Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Wu T; Broad Institute, Boston, MA, USA., Tsuji J; Broad Institute, Boston, MA, USA., Anderson K; Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Getz G; Broad Institute, Boston, MA, USA., Trippa L; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Richardson PG; Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Sklavenitis-Pistofidis R; Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute, Boston, MA, USA., Ghobrial IM; Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Publikováno v:
MedRxiv : the preprint server for health sciences [medRxiv] 2024 Apr 19. Date of Electronic Publication: 2024 Apr 19.
Autor:
Lee DJ; Department of Medicine, Massachusetts General Hospital, Boston, MA.; Harvard Medical School, Boston, MA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., El-Khoury H; Harvard Medical School, Boston, MA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Tramontano AC; Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA., Alberge JB; Harvard Medical School, Boston, MA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Perry J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Davis MI; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Horowitz E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Redd R; Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA., Sakrikar D; The Binding Site Inc, Rochester, MN., Barnidge D; The Binding Site Inc, Rochester, MN., Perkins MC; The Binding Site Group Ltd, Birmingham, United Kingdom., Harding S; The Binding Site Group Ltd, Birmingham, United Kingdom., Mucci L; Harvard T.H. Chan School of Public Health, Boston, MA., Rebbeck TR; Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA.; Harvard T.H. Chan School of Public Health, Boston, MA., Ghobrial IM; Harvard Medical School, Boston, MA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Center for Early Detection and Interception of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA., Marinac CR; Harvard Medical School, Boston, MA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Center for Early Detection and Interception of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA.
Publikováno v:
Blood advances [Blood Adv] 2024 Apr 09; Vol. 8 (7), pp. 1737-1746.
Autor:
Durand R; Molecular Vulnerabilities of Tumor Escape in B-cell Malignancies, Nantes Université, Centre National de la Recherche Scientifique (CNRS), INSERM, Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers (CRCI2NA), Nantes, France.; Hematology Department, Site de Recherche Intégrée sur le Cancer, Imaging and Longitudinal Investigations to Ameliorate Decision-making (SIRIC ILIAD), Nantes, France., Descamps G; Molecular Vulnerabilities of Tumor Escape in B-cell Malignancies, Nantes Université, Centre National de la Recherche Scientifique (CNRS), INSERM, Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers (CRCI2NA), Nantes, France.; Hematology Department, Site de Recherche Intégrée sur le Cancer, Imaging and Longitudinal Investigations to Ameliorate Decision-making (SIRIC ILIAD), Nantes, France., Bellanger C; Molecular Vulnerabilities of Tumor Escape in B-cell Malignancies, Nantes Université, Centre National de la Recherche Scientifique (CNRS), INSERM, Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers (CRCI2NA), Nantes, France.; Hematology Department, Site de Recherche Intégrée sur le Cancer, Imaging and Longitudinal Investigations to Ameliorate Decision-making (SIRIC ILIAD), Nantes, France., Dousset C; Hematology Department, Site de Recherche Intégrée sur le Cancer, Imaging and Longitudinal Investigations to Ameliorate Decision-making (SIRIC ILIAD), Nantes, France.; Hematology Department, Nantes Université, Centre Hospitalier Universitaire (CHU) de Nantes, CNRS, INSERM, CRCI2NA, Nantes, France., Maïga S; Hematology Department, Site de Recherche Intégrée sur le Cancer, Imaging and Longitudinal Investigations to Ameliorate Decision-making (SIRIC ILIAD), Nantes, France.; Hematology Department, Nantes Université, Centre Hospitalier Universitaire (CHU) de Nantes, CNRS, INSERM, CRCI2NA, Nantes, France., Alberge JB; Molecular Vulnerabilities of Tumor Escape in B-cell Malignancies, Nantes Université, Centre National de la Recherche Scientifique (CNRS), INSERM, Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers (CRCI2NA), Nantes, France.; Hematology Department, Site de Recherche Intégrée sur le Cancer, Imaging and Longitudinal Investigations to Ameliorate Decision-making (SIRIC ILIAD), Nantes, France., Derrien J; Molecular Vulnerabilities of Tumor Escape in B-cell Malignancies, Nantes Université, Centre National de la Recherche Scientifique (CNRS), INSERM, Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers (CRCI2NA), Nantes, France.; Hematology Department, Site de Recherche Intégrée sur le Cancer, Imaging and Longitudinal Investigations to Ameliorate Decision-making (SIRIC ILIAD), Nantes, France., Cruard J; Molecular Vulnerabilities of Tumor Escape in B-cell Malignancies, Nantes Université, Centre National de la Recherche Scientifique (CNRS), INSERM, Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers (CRCI2NA), Nantes, France.; Hematology Department, Site de Recherche Intégrée sur le Cancer, Imaging and Longitudinal Investigations to Ameliorate Decision-making (SIRIC ILIAD), Nantes, France., Minvielle S; Molecular Vulnerabilities of Tumor Escape in B-cell Malignancies, Nantes Université, Centre National de la Recherche Scientifique (CNRS), INSERM, Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers (CRCI2NA), Nantes, France.; Hematology Department, Site de Recherche Intégrée sur le Cancer, Imaging and Longitudinal Investigations to Ameliorate Decision-making (SIRIC ILIAD), Nantes, France., Lilli NL; Hematology Department, CHU de Nantes, Nantes, France., Godon C; Hematology Department, CHU de Nantes, Nantes, France., Le Bris Y; Hematology Department, Nantes Université, Centre Hospitalier Universitaire (CHU) de Nantes, CNRS, INSERM, CRCI2NA, Nantes, France., Tessoulin B; Hematology Department, Site de Recherche Intégrée sur le Cancer, Imaging and Longitudinal Investigations to Ameliorate Decision-making (SIRIC ILIAD), Nantes, France.; Hematology Department, Nantes Université, Centre Hospitalier Universitaire (CHU) de Nantes, CNRS, INSERM, CRCI2NA, Nantes, France., Amiot M; Molecular Vulnerabilities of Tumor Escape in B-cell Malignancies, Nantes Université, Centre National de la Recherche Scientifique (CNRS), INSERM, Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers (CRCI2NA), Nantes, France.; Hematology Department, Site de Recherche Intégrée sur le Cancer, Imaging and Longitudinal Investigations to Ameliorate Decision-making (SIRIC ILIAD), Nantes, France., Gomez-Bougie P; Hematology Department, Site de Recherche Intégrée sur le Cancer, Imaging and Longitudinal Investigations to Ameliorate Decision-making (SIRIC ILIAD), Nantes, France.; Hematology Department, Nantes Université, Centre Hospitalier Universitaire (CHU) de Nantes, CNRS, INSERM, CRCI2NA, Nantes, France., Touzeau C; Hematology Department, Site de Recherche Intégrée sur le Cancer, Imaging and Longitudinal Investigations to Ameliorate Decision-making (SIRIC ILIAD), Nantes, France.; Hematology Department, Nantes Université, Centre Hospitalier Universitaire (CHU) de Nantes, CNRS, INSERM, CRCI2NA, Nantes, France., Moreau P; Hematology Department, Site de Recherche Intégrée sur le Cancer, Imaging and Longitudinal Investigations to Ameliorate Decision-making (SIRIC ILIAD), Nantes, France.; Hematology Department, Nantes Université, Centre Hospitalier Universitaire (CHU) de Nantes, CNRS, INSERM, CRCI2NA, Nantes, France., Chiron D; Molecular Vulnerabilities of Tumor Escape in B-cell Malignancies, Nantes Université, Centre National de la Recherche Scientifique (CNRS), INSERM, Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers (CRCI2NA), Nantes, France.; Hematology Department, Site de Recherche Intégrée sur le Cancer, Imaging and Longitudinal Investigations to Ameliorate Decision-making (SIRIC ILIAD), Nantes, France., Moreau-Aubry A; Molecular Vulnerabilities of Tumor Escape in B-cell Malignancies, Nantes Université, Centre National de la Recherche Scientifique (CNRS), INSERM, Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers (CRCI2NA), Nantes, France.; Hematology Department, Site de Recherche Intégrée sur le Cancer, Imaging and Longitudinal Investigations to Ameliorate Decision-making (SIRIC ILIAD), Nantes, France., Pellat-Deceunynck C; Molecular Vulnerabilities of Tumor Escape in B-cell Malignancies, Nantes Université, Centre National de la Recherche Scientifique (CNRS), INSERM, Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers (CRCI2NA), Nantes, France.; Hematology Department, Site de Recherche Intégrée sur le Cancer, Imaging and Longitudinal Investigations to Ameliorate Decision-making (SIRIC ILIAD), Nantes, France.
Publikováno v:
Blood [Blood] 2024 Mar 28; Vol. 143 (13), pp. 1242-1258.
Autor:
Leblay N; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada., Ahn S; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada.; Department of Chemical and Petroleum Engineering, University of Calgary, Calgary, AB, Canada., Tilmont R; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada., Poorebrahim M; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada., Maity R; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada., Lee H; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada., Barakat E; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada., Alberge JB; Dana-Farber Cancer Institute, Boston, MA., Sinha S; Department of Comparative Biology and Experimental Medicine, Faculty of Veterinary Medicine, University of Calgary, Calgary, AB, Canada., Jaffer A; Department of Comparative Biology and Experimental Medicine, Faculty of Veterinary Medicine, University of Calgary, Calgary, AB, Canada., Barwick BG; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA.; Winship Cancer Institute, Emory University, Atlanta, GA., Boise LH; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA.; Winship Cancer Institute, Emory University, Atlanta, GA., Bahlis N; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada., Neri P; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada.
Publikováno v:
Blood [Blood] 2024 Jan 04; Vol. 143 (1), pp. 42-56.
Autor:
Lee H; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada., Ahn S; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada., Maity R; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada., Leblay N; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada., Ziccheddu B; Sylvester Comprehensive Cancer Center, Miami, FL, USA., Truger M; MLL Munich Leukemia Laboratory, Munich, Germany., Chojnacka M; Sylvester Comprehensive Cancer Center, Miami, FL, USA., Cirrincione A; Sylvester Comprehensive Cancer Center, Miami, FL, USA., Durante M; Sylvester Comprehensive Cancer Center, Miami, FL, USA., Tilmont R; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada., Barakat E; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada., Poorebrahim M; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada., Sinha S; Department of Comparative Biology and Experimental Medicine, Faculty of Veterinary Medicine, University of Calgary, Calgary, Alberta, Canada., McIntyre J; Precision Oncology Hub Laboratory, Tom Baker Cancer Centre, Calgary, Alberta, Canada., M Y Chan A; Precision Oncology Hub Laboratory, Tom Baker Cancer Centre, Calgary, Alberta, Canada., Wilson H; Precision Oncology Hub Laboratory, Tom Baker Cancer Centre, Calgary, Alberta, Canada., Kyman S; Translational Genomics Research Institute, Phoenix, AZ, USA., Krishnan A; City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Landgren O; Sylvester Comprehensive Cancer Center, Miami, FL, USA., Walter W; MLL Munich Leukemia Laboratory, Munich, Germany., Meggendorfer M; MLL Munich Leukemia Laboratory, Munich, Germany., Haferlach C; MLL Munich Leukemia Laboratory, Munich, Germany., Haferlach T; MLL Munich Leukemia Laboratory, Munich, Germany., Einsele H; Department of Internal Medicine 2, University Hospital of Würzburg, Würzburg, Germany., Kortüm MK; Department of Internal Medicine 2, University Hospital of Würzburg, Würzburg, Germany., Knop S; Department of Internal Medicine 2, University Hospital of Würzburg, Würzburg, Germany.; Department of Internal Medicine 5, Paracelsus Medical School, Nuremberg General Hospital, Nuremberg, Germany., Alberge JB; Harvard Medical School, Boston, MA, USA., Rosenwald A; Institute of Pathology, University of Würzburg, Würzburg, Germany., Keats JJ; Translational Genomics Research Institute, Phoenix, AZ, USA.; City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Rasche L; Department of Internal Medicine 2, University Hospital of Würzburg, Würzburg, Germany. Rasche_L@ukw.de.; Mildred Scheel Early Career Center, University Hospital of Würzburg, Würzburg, Germany. Rasche_L@ukw.de., Maura F; Sylvester Comprehensive Cancer Center, Miami, FL, USA. fxm557@med.miami.edu., Neri P; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada., Bahlis NJ; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada. nbahlis@ucalgary.ca.
Publikováno v:
Nature medicine [Nat Med] 2023 Sep; Vol. 29 (9), pp. 2295-2306. Date of Electronic Publication: 2023 Aug 31.
Autor:
Sklavenitis-Pistofidis R; Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece., Lightbody ED; Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Reidy M; Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Tsuji J; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Aranha MP; Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Heilpern-Mallory D; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Huynh D; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Chong SJF; Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Hackett L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Haradhvala NJ; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Wu T; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Su NK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Berrios B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Alberge JB; Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Dutta A; Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Davids MS; Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Papaioannou M; Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.; Hematology Unit, 1st Internal Medicine Department, AHEPA University Hospital, Thessaloniki, Greece., Getz G; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Department of Pathology, Massachusetts General Hospital, Boston, MA, USA., Ghobrial IM; Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Manier S; INSERM UMRS1277, CNRS UMR9020, Lille University, 59000, France.; Department of Hematology, CHU Lille, Lille University, 59000, France.
Publikováno v:
BioRxiv : the preprint server for biology [bioRxiv] 2023 Aug 03. Date of Electronic Publication: 2023 Aug 03.